Summary of Tonghua Dongbao’s 2025 Semi-Annual Report
Tonghua Dongbao Pharmaceutical Co., Ltd. 2025 Semi-annual Report Summary Company Code: 600867 Company Abbreviation: Tonghua Dongbao
Tonghua Dongbao Pharmaceutical Co., Ltd.
2025 Interim Report Summary
Summary of the 2025 Semi-Annual Report of Tonghua Dongbao Pharmaceutical Co., Ltd.
Section 1 Important Tips
1.1 The summary of this semi-annual report comes from the full text of the semi-annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should go to the http://www.sse.com.cn website to read the full text of the semi-annual report carefully.
1.2 The company’s board of directors, board of supervisors and directors, supervisors and senior managers guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability. 1.3 All directors of the company shall attend the board meeting.
1.4 This semi-annual report has not been audited.
1.5 The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital passed by the board of directors
None
Section 2 Basic Information of the Company
2.1 Company Profile
Company Stock Profile
Type of stock Stock exchange on which the stock is listed Stock abbreviation Stock code A shares Shanghai Stock Exchange Tonghua Dongbao 600867 Contact and contact information Secretary of the Board of Directors Securities Affairs Representative Li Jiahong (Chairman Acts as Secretary of the Board of Directors)
Name Gu Liping
book responsibilities)
Phone 0435-5088025 0435-5088126
Office address Dongbao Xincun, Tonghua County, Jilin Province Securities Department, Dongbao Xincun, Tonghua County, Jilin Province
Email [email protected] [email protected] 2.2 Main financial data
Unit: Yuan Currency: RMB The end of the reporting period compared with the end of the previous year The end of the reporting period The end of the previous year
Final increase/decrease (%) in total assets
7,847,110,023.17 7,378,510,669.69 6.35 Net assets attributable to shareholders of listed companies
6,120,967,758.68 6,383,540,358.15 -4.11
Summary of the 2025 Semi-Annual Report of Tonghua Dongbao Pharmaceutical Co., Ltd.
This reporting period is better than the same period last year. This reporting period is better than the same period last year.
Increase or decrease(%)
operating income
1,373,490,568.29 740,012,638.31 85.60Total profit
254,931,913.37 -298,330,282.32 Not applicable Net profit attributable to shareholders of listed companies
217,758,063.83 -230,490,246.48 Not applicable to non-deductions attributable to shareholders of listed companies
220,819,402.05 -228,792,943.27 Net profit not applicable to recurring gains and losses
Net cash flow from operating activities
317,360,535.65 128,224,217.42 147.50 Weighted average return on equity (%)
3.35 -3.32 Not applicable Basic earnings per share (yuan/share)
0.11 -0.12 Not applicable Diluted earnings per share (yuan/share)
0.11 -0.12 Not applicable
2.3 List of shareholdings of the top 10 shareholders
Unit: Share Total number of shareholders (households) as of the end of the reporting period 86,536 Shareholding status of the top 10 shareholders
Limited holding
Shareholder nature Shareholding ratio Shareholding Name of shareholder pledged, marked or frozen Sale conditions
Quality Example (%) Quantity Number of shares Number of shares
Domestic non-
Dongbao Industrial Group Co., Ltd. State-owned Law 31.13 609,649,596 0 Pledge 565,939,472
people
Tianjin Zhenyi Equity Investment Partnership
Others 9.35 183,058,967 0 None 0 (limited partnership)
Abu Dhabi Investment Authority Others 1.63 31,931,312 0 None 0 Bank of China Co., Ltd. - Recruitment
Shangguo Securities Biomedical Index Grading Certificate Others 1.03 20,246,377 0 None 0 Bond Investment Fund
Hong Kong Securities Clearing Company Limited Others 1.02 20,005,256 0 None 0 Agricultural Bank of China Limited
- CSI 500 Trading Open Index Others 0.89 17,406,834 0 None 0 Securities Investment Fund
within the territory of
Li Yikui 0.58 11,328,579 0 None 0
Ranren
Bank of Shanghai Co., Ltd.-Bank
Huazhong Securities Innovative Drug Industry Transaction Type Other 0.57 11,071,311 0 None 0 Open-ended Index Securities Investment Fund
Summary of the 2025 Semi-Annual Report of Tonghua Dongbao Pharmaceutical Co., Ltd.
CITIC Securities Co., Ltd.
- Tianhong National Securities Biomedical Trading Type Others 0.39 7,562,600 0 None 0 Open-end Index Securities Investment Fund
Domestic non-
Tonghua Jixiang Chuangying Investment Management Center State-owned Law 0.37 7,318,163 0 None 0 people
The company’s controlling shareholder Dongbao Industrial Group Co., Ltd. and the company
The actual controller of the company, Li Yikui, is a person acting in concert. The company has no explanation of the above-mentioned shareholder affiliation or concerted action.
Know whether there are related relationships among other shareholders or whether they belong to
People acting in concert.
Description of preference shareholders whose voting rights have been restored and the number of shares they hold
None
2.4 Total number of preference shareholders and top 10 preference shareholders as of the end of the reporting period
□Applicable √Not applicable
2.5 Changes in controlling shareholders or actual controllers
□Applicable √Not applicable
2.6 Status of bonds existing on the date of approval of the semi-annual report
□Applicable √Not applicable
Section 3 Important Matters
The company shall, in accordance with the principle of materiality, explain the major changes in the company's operating conditions during the reporting period, as well as the matters that occurred during the reporting period that have a significant impact on the company's operating conditions and are expected to have a significant impact in the future.
□Applicable √Not applicable